FDA
-
-
-
-
-
-
-
Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020
-
-
-
-
-
-
-
Stemline Therapeutics (STML) ighlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at ASH
-
-
-
-
-
-
-
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
-
-
-
-
-
-
-
Stemline Therapeutics (STML) Prices 5M Share Common Offering at $15.25/Sh
-
-
-
-
-
-
-
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019
-
-
-
-
-
-
-
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress
-
-
-
-
-
-
-
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline
-
322,904 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

